14.26
Eton Pharmaceuticals Inc Borsa (ETON) Ultime notizie
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Increase in Short Interest - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Has Found A Path To Profitability - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Retail investors who have a significant stake must be disappointed along with institutions after Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) market cap dropped by US$35m - simplywall.st
(ETON) Technical Data - news.stocktradersdaily.com
Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma - MSN
Eton sells overseas rights for hormone disorder drug (ETON) - Seeking Alpha
Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals - MarketScreener
Eton Pharma Out-Licenses International Rights To Increlex To Esteve Pharma - Nasdaq
Eton Pharmaceuticals out-licenses international rights to Increlex - TipRanks
Eton Pharmaceuticals IncEsteve To Pay Eur4 Million Up Front For Increlex RightsSEC Filing - MarketScreener
Eton Pharmaceuticals licenses Increlex rights abroad - Investing.com
Eton Pharmaceuticals licenses Increlex rights abroad By Investing.com - Investing.com UK
Eton Pharmaceuticals Out-Licenses International Rights to Increlex® - GlobeNewswire
Major Pharma Deal: Eton's Smart Move Unlocks Global Market for Rare Disease Treatment - Stock Titan
Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times
REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency… - Informazione.it
Research Analysts Set Expectations for ETON Q2 Earnings - Defense World
Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus
B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - MarketScreener
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo
Eton Pharmaceuticals Reports Record Q4 Revenue Growth - TipRanks
Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions - TipRanks
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - TradingView
Eton Pharmaceuticals Reports Record Q4 2024 Revenue and Successful Product Launches Ahead of Investor Day Conference Call - Nasdaq
Eton Pharmaceuticals Achieves 16th Straight Quarter of Growth, Doubles Product Portfolio - StockTitan
Earnings Scheduled For March 18, 2025 - Benzinga
Eton Pharmaceuticals (NASDAQ:ETON) shareholder returns have been incredible, earning 421% in 5 years - Simply Wall St
(ETON) On The My Stocks Page - news.stocktradersdaily.com
Eton Pharmaceuticals nears NDA submission for new drug By Investing.com - Investing.com Australia
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch - Benzinga India
Eton Pharma rises on study results for rare disease drug - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Eton's Diabetes Drug Candidate Passes Bioequivalence Study -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Eton Pharmaceuticals nears NDA submission for new drug - Investing.com India
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Eagle-Tribune
Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial - StockTitan
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday - Defense World
Trading (ETON) With Integrated Risk Controls - news.stocktradersdaily.com
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN® - The Manila Times
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):